

REMARKS/ARGUMENTS

Claims 1-3, 5-8 and 14-26 are pending following entry of the above amendments.

The amendment to claim 1 finds support in original claim 4 and the new claims find support in the specification as follows:

Claims 14-15: page 20, lines 5-6

Claim 16: page 22, lines 30-31

Claims 17-19: page 23, lines 3-7

Claim 20: page 20, line 7

Claims 21-23 page 25, lines 1-3

Claims 24-26; page 25, lines 3-5

Applicants also submit herewith a Supplemental Information Disclosure Statement and accompanying PTO Form 1449.

REJECTION OF THE CLAIMS UNDER 35 U.S.C. 112, SECOND PARAGRAPH

Claims 1-8 were rejected as the use of the term “optionally” in claim 1 was alleged to render it unclear as to whether the lipophilic substituent is necessary for the operation of the invention.

In reply, Applicants respectfully submit that this rejection is rendered moot by the amendment to claim 1 which makes clear that the GLP-1 compounds included in the formulations of the invention have a lipophilic substituent attached and that this attachment may optionally occur via a spacer.

REJECTION OF THE CLAIMS UNDER 35 U.S.C. 103(a)

Claims 1 and 2 were rejected under section 103(a) as obvious over US patent No. 6,380,357.

In reply, Applicants respectfully submit that this rejection has been rendered moot by the incorporation of the limitation of now cancelled claim 4 into independent claim 1.


Attorney Docket No.: 6116.200-US
Express Mail Label No.: EV 409530474 US

In view of the above amendments and remarks, it is believed that the above application is in condition for allowance.

Early and favorable consideration by the Examiner is respectfully solicited.

Respectfully submitted,

Date: February 13, 2004



Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE